Wylie Burke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8576373/publications.pdf

Version: 2024-02-01

186 papers	12,774 citations	30047 54 h-index	25770 108 g-index
189 all docs	189 docs citations	189 times ranked	12444 citing authors

#	Article	IF	Citations
1	Precision medicine research with American Indian and Alaska Native communities: Results of a deliberative engagement with tribal leaders. Genetics in Medicine, 2022, 24, 622-630.	1.1	10
2	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	3.8	28
3	2021 McKusick Leadership Award: Learning from communities. American Journal of Human Genetics, 2022, 109, 390-392.	2.6	0
4	Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants. Journal of Empirical Research on Human Research Ethics, 2022, 17, 4-14.	0.6	3
5	The Challenge of Genetic Variants of Uncertain Clinical Significance. Annals of Internal Medicine, 2022, 175, 994-1000.	2.0	29
6	Communal Coping as a Strategy to Enhance Family Engagement in Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2022, , 101161CIRCGEN121003541.	1.6	0
7	Is there a way to reduce the inequity in variant interpretation on the basis of ancestry?. American Journal of Human Genetics, 2022, 109, 981-988.	2.6	13
8	Response to Faulkner et al.. Genetics in Medicine, 2021, 23, 243.	1.1	0
9	Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review. Journal of the American Society of Nephrology: JASN, 2021, 32, 1765-1778.	3.0	13
10	Utility and Diversity: Challenges for Genomic Medicine. Annual Review of Genomics and Human Genetics, 2021, 22, 1-24.	2.5	12
11	Solidarity: A Missing Component of Research Ethics. American Journal of Bioethics, 2021, 21, 20-21.	0.5	0
12	Toward better governance of human genomic data. Nature Genetics, 2021, 53, 2-8.	9.4	31
13	Is there a duty to reinterpret genetic data? The ethical dimensions. Genetics in Medicine, 2020, 22, 633-639.	1.1	51
14	Predictive and Precision Medicine with Genomic Data. Clinical Chemistry, 2020, 66, 33-41.	1.5	7
15	At the Research-Clinical Interface. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1181-1189.	2.2	9
16	Preimplantation Genetic Testing for Genetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1231-1233.	2.2	1
17	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
18	Exploring relativesâ€™ perceptions of participation, ethics, and communication in a patientâ€driven study for hereditary cancer variant reclassification. Journal of Genetic Counseling, 2020, 29, 857-866.	0.9	4

#	Article	IF	Citations
19	Experiences of patients seeking to participate in variant of uncertain significance reclassification research. Journal of Community Genetics, 2019, 10, 189-196.	0.5	23
20	Patient goals, motivations, and attitudes in a patientâ€driven variant reclassification study. Journal of Genetic Counseling, 2019, 28, 558-569.	0.9	5
21	Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemporary Clinical Trials, 2019, 84, 105820.	0.8	6
22	Genomes in Context. American Journal of Bioethics, 2019, 19, 66-67.	0.5	0
23	ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 2019, 21, 2404.	1.1	2
24	Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines. Genetics in Medicine, 2019, 21, 2431-2438.	1.1	13
25	Precision medicine and health disparities: The case of pediatric acute lymphoblastic leukemia. Nursing Outlook, 2019, 67, 331-336.	1.5	4
26	Consent insufficient for data release. Science, 2019, 364, 445-446.	6.0	9
27	You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 526-530.	3.0	31
28	The Precautionary Principle for Shift-Work Research and Decision-Making. Public Health Ethics, 2019, 12, 44-53.	0.4	4
29	Practice Implications of Expanded Genetic Testing in Oncology. Cancer Investigation, 2019, 37, 39-45.	0.6	8
30	Access and Management: Indigenous Perspectives on Genomic Data Sharing. Ethnicity and Disease, 2019, 29, 659-668.	1.0	31
31	Data Management in Health-Related Research Involving Indigenous Communities in the United States and Canada: A Scoping Review. Frontiers in Genetics, 2019, 10, 942.	1.1	11
32	Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions. American Journal of Nephrology, 2019, 50, 303-311.	1.4	22
33	Can Precision Medicine Reduce the Burden of Diabetes?. Ethnicity and Disease, 2019, 29, 669-674.	1.0	7
34	The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. Journal of Genetic Counseling, 2019, 28, 477-490.	0.9	39
35	Randomized trial of a web-based survivor intervention on melanoma prevention behaviors of first-degree relatives. Cancer Causes and Control, 2019, 30, 225-233.	0.8	18
36	Pharmacogenomics in Indigenous Populations. FASEB Journal, 2019, 33, 217.2.	0.2	1

#	Article	IF	Citations
37	Authorsâ€™ Response Sedation Safety Has Many Perspectives, and the Discussion is Ongoing. Pediatrics, 2018, 141, .	1.0	0
38	Clinicianâ€Stakeholdersâ€™ Perspectives on Using Patient Portals to Return Lynch Syndrome Screening Results. Journal of Genetic Counseling, 2018, 27, 349-357.	0.9	9
39	Informed Consent in Translational Genomics: Insufficient Without Trustworthy Governance. Journal of Law, Medicine and Ethics, 2018, 46, 79-86.	0.4	18
40	Pathways from autism spectrum disorder diagnosis to genetic testing. Genetics in Medicine, 2018, 20, 737-744.	1.1	29
41	Navigating the researchâ€“clinical interface in genomic medicine: analysis from the CSER Consortium. Genetics in Medicine, 2018, 20, 545-553.	1.1	34
42	Responsible Research With Urban American Indians and Alaska Natives. American Journal of Public Health, 2018, 108, 1613-1616.	1.5	20
43	Standardizing return of participant results. Science, 2018, 362, 759-760.	6.0	3
44	Making Sense of the Genome Remains a Work in Progress. JAMA - Journal of the American Medical Association, 2018, 320, 1247.	3.8	5
45	P450 Pharmacogenetics in Indigenous North American Populations. Journal of Personalized Medicine, 2018, 8, 9.	1.1	22
46	Whole-Genome Sequencing in Healthy People. Mayo Clinic Proceedings, 2017, 92, 159-172.	1.4	40
47	Carnitine palmitoyltransferase 1A P479L and infant death: policy implications of emerging data. Genetics in Medicine, 2017, 19, 851-857.	1.1	11
48	Communication Among Melanoma Family Members. Journal of Health Communication, 2017, 22, 198-204.	1.2	13
49	All in the family? Communication of cancer survivors with their families. Familial Cancer, 2017, 16, 597-603.	0.9	23
50	Uninformed consent in nutrigenomic research. European Journal of Human Genetics, 2017, 25, 789-790.	1.4	4
51	Identifying â€œownershipâ€•through role descriptions to support implementing universal colorectal cancer tumor screening for Lynch syndrome. Genetics in Medicine, 2017, 19, 1236-1244.	1.1	13
52	Genomics, Health Disparities, and Missed Opportunities for the Nationâ€™s Research Agenda. JAMA - Journal of the American Medical Association, 2017, 317, 1831.	3.8	70
53	Implementing Precision Medicine: The Ethical Challenges. Trends in Pharmacological Sciences, 2017, 38, 8-14.	4.0	39
54	Response to Koeller et al.. Genetics in Medicine, 2017, 19, 1380-1380.	1.1	0

#	Article	IF	Citations
55	Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	41
56	Clinical Genetic Testing for APOL1 : Are we There Yet?. Seminars in Nephrology, 2017, 37, 552-557.	0.6	29
57	Ethics Rounds: Death After Pediatric Dental Anesthesia: An Avoidable Tragedy?. Pediatrics, 2017, 140, .	1.0	25
58	Commentary to â€œMy Identical Twin Sequenced Our Genomeâ€• Cautionary Genomics. Journal of Genetic Counseling, 2017, 26, 279-280.	0.9	1
59	Is â€œincidental findingâ€•the best term?: a study of patientsâ€™ preferences. Genetics in Medicine, 2017, 19, 176-181.	1.1	34
60	Dietary and genetic influences on hemostasis in a Yupâ€™ik Alaska Native population. PLoS ONE, 2017, 12, e0173616.	1.1	5
61	Avoiding the Technological Imperative: Criteria for Genetic Screening Programs. OBM Genetics, 2017, 01, 1-1.	0.2	6
62	Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. Progress in Community Health Partnerships: Research, Education, and Action, 2016, 10, 173-183.	0.2	14
63	Initiation of universal tumor screening for <scp>L</scp>ynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. Cancer, 2016, 122, 393-401.	2.0	28
64	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
65	If you build it, they will come: unintended future uses of organised health data collections. BMC Medical Ethics, 2016, 17, 54.	1.0	47
66	Patient safety in genomic medicine: an exploratory study. Genetics in Medicine, 2016, 18, 1136-1142.	1.1	15
67	Mapping the Ethics of Translational Genomics: Situating Return of Results and Navigating the Research-Clinical Divide. Journal of Law, Medicine and Ethics, 2015, 43, 486-501.	0.4	47
68	Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics, 2015, 16, 227-237.	0.6	23
69	Closing the Gap between Knowledge and Clinical Application: Challenges for Genomic Translation. PLoS Genetics, 2015, 11, e1004978.	1.5	36
70	Community dissemination and genetic research: Moving beyond results reporting. American Journal of Medical Genetics, Part A, 2015, 167, 1542-1550.	0.7	28
71	Effects of web-based intervention on risk reduction behaviors in melanoma survivors. Journal of Cancer Survivorship, 2015, 9, 279-286.	1.5	39
72	Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2015, 33, 2084-2091.	0.8	118

#	Article	IF	Citations
73	Response to Strong. Genetics in Medicine, 2015, 17, 682-683.	1.1	0
74	Response to Phillips et al.. Genetics in Medicine, 2015, 17, 315-315.	1.1	0
75	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
76	The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genetics in Medicine, 2015, 17, 587-595.	1.1	101
77	WHAT DNA CAN AND CANNOT SAY: PERSPECTIVES OF IMMIGRANT FAMILIES ABOUT THE USE OF GENETIC TESTING IN IMMIGRATION. Stanford Law & Policy Review, 2015, 26, 597-638.	0.5	2
78	Exploring pathways to trust: a tribal perspective on data sharing. Genetics in Medicine, 2014, 16, 820-826.	1.1	77
79	Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics, 2014, 15, 1235-1241.	0.6	37
80	Regulatory changes raise troubling questions for genomic testing. Genetics in Medicine, 2014, 16, 799-803.	1.1	28
81	A Call for Accurate Pharmacogenetic Labeling. JAMA Internal Medicine, 2014, 174, 1945.	2.6	2
82	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	2.6	342
83	Genetic Tests: Clinical Validity and Clinical Utility. Current Protocols in Human Genetics, 2014, 81, 9.15.1-8.	3.5	68
84	Essential elements of personalized medicine. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 193-197.	0.8	40
85	Comparative effectiveness of next generation genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials, 2014, 39, 1-8.	0.8	17
86	Return of results: Ethical and legal distinctions between research and clinical care. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 105-111.	0.7	92
87	Native Hawaiian Views on Biobanking. Journal of Cancer Education, 2014, 29, 570-576.	0.6	43
88	Recommendations for returning genomic incidental findings? We need to talk!. Genetics in Medicine, 2013, 15, 854-859.	1.1	272
89	Actionable, Pathogenic Incidental Findings in 1,000 Participantsâ€™ Exomes. American Journal of Human Genetics, 2013, 93, 631-640.	2.6	342
90	Maternal perspectives on the return of genetic results: Context matters. American Journal of Medical Genetics, Part A, 2013, 161, 38-47.	0.7	23

#	Article	IF	Citations
91	Primary-care physiciansâ€™ access to genetic specialists: anÂimpediment to the routine use of genomic medicine?. Genetics in Medicine, 2013, 15, 513-514.	1.1	26
92	Return of incidental findings in genomic medicine: measuring what patients valueâ€"development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genetics in Medicine, 2013, 15, 873-881.	1.1	72
93	Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 2013, 15, 860-867.	1.1	99
94	Risk, Reward, and the Double-Edged Sword: Perspectives on Pharmacogenetic Research and Clinical Testing Among Alaska Native People. American Journal of Public Health, 2013, 103, 2220-2225.	1.5	38
95	Genetics researchersâ€™ and IRB professionalsâ€™ attitudes toward genetic research review: a comparative analysis. Genetics in Medicine, 2012, 14, 236-242.	1.1	35
96	Predictors of recruited melanoma families into a behavioral intervention project. Contemporary Clinical Trials, 2012, 33, 85-92.	0.8	13
97	Next-generation sequencing in the clinic: are we ready?. Nature Reviews Genetics, 2012, 13, 818-824.	7.7	115
98	Values in Translation: How Asking the Right Questions Can Move Translational Science Toward Greater Health Impact. Clinical and Translational Science, 2012, 5, 445-451.	1.5	22
99	From Leaky Pipeline to Irrigation System: Minority Education Through the Lens of Community-Based Participatory Research. Progress in Community Health Partnerships: Research, Education, and Action, 2012, 6, 471-479.	0.2	20
100	Systems medicine and the public's health. Genome Medicine, 2011, 3, 47.	3.6	8
101	Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 2011, 13, 597-605.	1.1	297
102	Teaching with single nucleotide polymorphisms: Learning the right lessons. Genetics in Medicine, 2011, 13, 17-18.	1.1	4
103	Implementation outcomes of a multiinstitutional web-based ethical, legal, and social implications genetics curriculum for primary care residents in three specialties. Genetics in Medicine, 2011, 13, 553-562.	1.1	10
104	Stakeholder Perspectives on a Risk-Benefit Framework for Genetic Testing. Public Health Genomics, 2011, 14, 59-67.	0.6	17
105	Responseâ€"The Risks and Benefits of Re-Consent. Science, 2011, 332, 306-306.	6.0	5
106	Genetic Screening. Epidemiologic Reviews, 2011, 33, 148-164.	1.3	63
107	Population description and its role in the interpretation of genetic association. Human Genetics, 2010, 127, 563-572.	1.8	21
108	Researcher Perspectives on Disclosure of Incidental Findings in Genetic Research. Journal of Empirical Research on Human Research Ethics, 2010, 5, 31-41.	0.6	57

#	Article	IF	Citations
109	Debating Clinical Utility. Public Health Genomics, 2010, 13, 215-223.	0.6	56
110	Responseâ€"Regulating Genetic Tests: Who Owns the Data?. Science, 2010, 330, 1626-1627.	6.0	0
111	A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine, 2010, 12, 686-693.	1.1	83
112	Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and â€œpersonalizedâ€•medicine?. Genetics in Medicine, 2010, 12, 785-791.	1.1	95
113	Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants. Circulation: Cardiovascular Genetics, 2010, 3, 574-580.	5.1	328
114	Breast cancer risk communication: Assessment of primary care physicians by standardized patients. Genetics in Medicine, 2009, 11, 735-741.	1.1	26
115	Genetic assessment of breast cancer risk in primary care practice. American Journal of Medical Genetics, Part A, 2009, 149A, 349-356.	0.7	60
116	Clinical Validity and Clinical Utility of Genetic Tests. Current Protocols in Human Genetics, 2009, 60, Unit 9.15.	3.5	17
117	Cytochrome P450 Enzyme Polymorphism Frequency in Indigenous and Native American Populations: A Systematic Review. Public Health Genomics, 2008, 11, 141-149.	0.6	36
118	ASHG Presidential Address: Who Is under the Umbrellaâ€"and Why Are We Here?. American Journal of Human Genetics, 2008, 82, 1029-1031.	2.6	2
119	Translational Genomics: Seeking a Shared Vision of Benefit. American Journal of Bioethics, 2008, 8, 54-56.	0.5	18
120	An Unwelcome Side Effect of Direct-to-Consumer Personal Genome Testing. JAMA - Journal of the American Medical Association, 2008, 300, 2669.	3.8	232
121	Educational Needs in Genetic Medicine: Primary Care Perspectives. Public Health Genomics, 2008, 11, 160-165.	0.6	33
122	Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genetics in Medicine, 2008, 10, 404-414.	1.1	129
123	Defining purpose: a key step in genetic test evaluation. Genetics in Medicine, 2007, 9, 675-681.	1.1	27
124	Will Genomics Widen or Help Heal the Schism Between Medicine and Public Health?. American Journal of Preventive Medicine, 2007, 33, 310-317.	1.6	57
125	ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States. American Journal of Human Genetics, 2007, 81, 635-637.	2.6	142
126	Personalized Medicine in the Era of Genomics. JAMA - Journal of the American Medical Association, 2007, 298, 1682.	3.8	174

#	Article	IF	Citations
127	American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. Ca-A Cancer Journal for Clinicians, 2007, 57, 75-89.	157.7	2,234
128	Anticipating dissemination of cancer genomics in public health: A theoretical approach to psychosocial and behavioral challenges. Annals of Behavioral Medicine, 2007, 34, 275-286.	1.7	24
129	Bioethics of Genetic Testing for Hereditary Breast Cancer. , 2007, , 35-51.		2
130	Ethical issues arising from the participation of children in genetic research. Journal of Pediatrics, 2006, 149, S34-S38.	0.9	79
131	Ethical Obligations and Counseling Challenges in Cancer Genetics. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 185-191.	2.3	9
132	Ethical Issues in Ecogenetics. , 2006, , 381-395.		0
133	Effects of counseling Ashkenazi Jewish women about breast cancer risk.. Cultural Diversity and Ethnic Minority Psychology, 2006, 12, 45-56.	1.3	18
134	The path from genome-based research to population health: Development of an international public health genomics network. Genetics in Medicine, 2006, 8, 451-458.	1.1	152
135	Genetics as a tool to improve cancer outcomes: ethics and policy. Nature Reviews Cancer, 2006, 6, 476-482.	12.8	20
136	Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1507.	3.8	561
137	Newborn Screening Technology: Proceed With Caution. Pediatrics, 2006, 117, 1793-1799.	1.0	132
138	â€˜That's like chopping off a finger because youâ€™re afraid it might get brokenâ€™: Disease and illness in women's views of prophylactic mastectomy. Social Science and Medicine, 2005, 61, 1106-1117.	1.8	15
139	Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?. Genetics in Medicine, 2005, 7, 380-389.	1.1	62
140	Contributions of Public Health to Genetics Education for Health Care Professionals. Health Education and Behavior, 2005, 32, 668-675.	1.3	14
141	GENETIC TESTING IN PRIMARY CARE. Annual Review of Genomics and Human Genetics, 2004, 5, 1-14.	2.5	64
142	Reconsidering the family history in primary care. Journal of General Internal Medicine, 2004, 19, 273-280.	1.3	302
143	Ensuring the appropriate use of genetic tests. Nature Reviews Genetics, 2004, 5, 955-959.	7.7	122
144	Breast cancer risk counseling improves womenâ€™s functioning. Patient Education and Counseling, 2004, 53, 79-86.	1.0	60

#	Article	IF	Citations
145	Ethical issues in identifying and recruiting participants for familial genetic research. American Journal of Medical Genetics Part A, 2004, 130A, 424-431.	2.4	55
146	Clinical Validity and Clinical Utility of Genetic Tests. Current Protocols in Human Genetics, 2004, 42, Unit9.15.	3.5	1
147	Changing the Clinical Management of Hereditary Hemochromatosis. Archives of Internal Medicine, 2004, 164, 957.	4.3	10
148	Family history as a predictor of asthma risk. American Journal of Preventive Medicine, 2003, 24, 160-169.	1.6	184
149	Achieving utility with family history. American Journal of Preventive Medicine, 2003, 24, 177-182.	1.6	15
150	RESPONSE: Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance. Journal of the National Cancer Institute, 2003, 95, 78-79.	3.0	4
151	Genomics as a Probe for Disease Biology. New England Journal of Medicine, 2003, 349, 969-974.	13.9	82
152	Hereditary hemochromatosis: Perspectives of public health, medical genetics, and primary care. Genetics in Medicine, 2003, 5, 1-8.	1.1	24
153	An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genetics in Medicine, 2003, 5, 353-363.	1.1	40
154	Genetic Risk in Context: Calculating the Penetrance of BRCA1 and BRCA2 Mutations. Journal of the National Cancer Institute, 2002, 94, 1185-1187.	3.0	20
155	Genetic Test Evaluation: Information Needs of Clinicians, Policy Makers, and the Public. American Journal of Epidemiology, 2002, 156, 311-318.	1.6	160
156	Genetics in Primary Care: A USA Faculty Development Initiative. Public Health Genomics, 2002, 5, 138-146.	1.0	57
157	Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. Genetics in Medicine, 2002, 4, 359-365.	1.1	36
158	Genetic Testing. New England Journal of Medicine, 2002, 347, 1867-1875.	13.9	161
159	Teaching genetics in primary care through a transatlantic videoconference. Nature Reviews Genetics, 2002, 3, 568-568.	7.7	0
160	Genetics education for primary-care providers. Nature Reviews Genetics, 2002, 3, 561-566.	7.7	103
161	Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the population. Best Practice and Research in Clinical Haematology, 2002, 15, 315-28.	0.7	6
162	Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. American Journal of Medical Genetics Part A, 2001, 99, 99-110.	2.4	104

#	Article	IF	Citations
163	Categorizing genetic tests to identify their ethical, legal, and social implications. American Journal of Medical Genetics Part A, 2001, 106, 233-240.	2.4	113
164	Participation in Breast Cancer Genetic Counseling: The Influence of Educational Level, Ethnic Background, and Risk Perception. Journal of Genetic Counseling, 2001, 10, 215-231.	0.9	42
165	Oncologists' opinions on genetic testing for breast and ovarian cancer. Genetics in Medicine, 2001, 3, 120-125.	1.1	18
166	Application of Population Screening Principles to Genetic Screening for Adult-Onset Conditions. Genetic Testing and Molecular Biomarkers, 2001, 5, 201-211.	1.7	61
167	Iron deficiency and iron overload: effects of diet and genes. Proceedings of the Nutrition Society, 2001, 60, 73-80.	0.4	22
168	Challenges in communicating genetics: A public health approach. Genetics in Medicine, 2000, 2, 198-202.	1.1	63
169	Genetic counseling for women with an intermediate family history of breast cancer. , 2000, 90, 361-368.		75
170	Delivery of primary care to women. Journal of General Internal Medicine, 2000, 15, 8-15.	1.3	23
171	Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genetics in Medicine, 2000, 2, 271-277.	1.1	73
172	Screening for hereditary hemochromatosis: are DNA-based tests the answer?. Trends in Molecular Medicine, 1999, 5, 428-430.	2.6	8
173	Screening for hemochromatosis:. American Journal of Preventive Medicine, 1999, 16, 134-140.	1.6	35
174	Testing for inherited susceptibility to breast cancer: A survey of informed consent forms for BRCA1 and BRCA2 mutation testing. , 1998, 75, 82-87.		19
175	What influences career choices among graduates of a primary care training program?. Journal of General Internal Medicine, 1998, 13, 257-261.	1.3	35
176	Hereditary Hemochromatosis. JAMA - Journal of the American Medical Association, 1998, 280, 172.	3.8	253
177	Uncertainties in Genetic Testing for Chronic Disease. JAMA - Journal of the American Medical Association, 1998, 280, 1525-7.	3.8	46
178	Hemochromatosis: genetics helps to define a multifactorial disease. Clinical Genetics, 1998, 54, 1-9.	1.0	32
179	Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer. JAMA - Journal of the American Medical Association, 1997, 277, 915.	3.8	381
180	Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer. JAMA - Journal of the American Medical Association, 1997, 277, 997.	3.8	548

#	Article	IF	Citations
181	Sensation of smell does not determine nutritional status in patients with cystic fibrosis. , 1997, 24, 52-56.		9
182	Breast carcinoma genetics from a primary care perspective. Cancer, 1997, 80, 621-626.	2.0	3
183	The advent of the â€˜unpatientsâ€™. Nature Medicine, 1996, 2, 622-624.	15.2	65
184	Variable Severity of Pulmonary Disease in Adults with Identical Cystic Fibrosis Mutations. Chest, 1992, 102, 506-509.	0.4	55
185	Hypertension and the Genetics of Red Cell Membrane Abnormalities. Novartis Foundation Symposium, 1987, 130, 150-166.	1.2	14
186	Temporal order in yeast chromosome replication. Cell, 1975, 5, 263-269.	13.5	72